- Home
- MCR vs LYEL Comparison
MCR vs LYEL Comparison
Compare MCR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCR | LYEL |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCR | LYEL |
|---|---|---|
| Price | $6.06 | $20.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | ★ 87.7K | 78.6K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17,438.13 |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.57 | $0.39 |
| 52 Week High | $6.57 | $45.00 |
Technical Indicators
Market Signals| Indicator | MCR | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 43.09 |
| Support Level | $6.00 | $16.20 |
| Resistance Level | $6.38 | $27.30 |
| Average True Range (ATR) | 0.08 | 1.98 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 59.68 | 35.02 |
Price Performance
Historical ComparisonAbout MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.